Sugemalimab Plus Chemotherapy Earns UK Approval in First-Line Metastatic NSCLC
First-line sugemalimab plus chemotherapy has received UK approval for metastatic NSCLC without EGFR-sensitizing mutations or ALK/ROS1/RET alterations.
Related Articles
Brown Foundation Award for Excellence in Oncology Nursing honors Tiffany Richards
The University of Texas MD Anderson Cancer Center today honored Tiffany Richards, Ph.D., A.P.R.N., A.N.P.-B.C., A.O.C.N.P., with the 2024 Brown Foundation Award for Excellence in…
Balancing Risk and Efficacy in Follicular Lymphoma Treatment
Christopher R. Flowers, MD, MS, discusses what the current treatment landscape of follicular lymphoma looks like.
FDA Grants Regenerative Medicine Advanced Therapy Designation to ALLO-316 in CD70+ Advanced RCC
The FDA has granted regenerative medicine advanced therapy to ALLO-316 in CD70-positive advanced or metastatic renal cell carcinoma.
FDA Delays Decision Date for Zenocutuzumab in Lung, Pancreatic Cancer
The FDA extended the Prescription Drug User Fee Act date for the biologics license application seeking approval of zenocutuzumab for NRG1-positive lung and pancreatic cancer.
Conversations on Cancer – Pediatric Cancers: Navigating the Challenges Together
Take this survey powered by surveymonkey.com. Create your own surveys for free.
213 CNOS to know | 2024
Becker’s is thrilled to honor healthcare CNOs. Chief nursing officers are responsible for tackling nurse staffing shortages, managing nursing budgets and more.
Mutant KRAS in Circulating Tumor DNA as a Biomarker in… : Annals of Surgery
round Data: Increasingly, ctDNA is being used for clinical decision-making in a variety of solid malignancies. However, the detection and prognostic value of KRAS ctDNA…
Genetic Risk Score Offers Insight Into CLL Predisposition
Susan L. Slager, PhD, discussed the etiology and inherited genetic factors that are associated with the risk of chronic lymphocytic leukemia.
Evolving Paradigms In Advanced Ovarian Cancer Care | Optimizing Physician and Patient Conversations by Understanding Perspectives
For the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA -mutated (g BRCA m or s BRCA m) advanced…